Skip to main content
SpringerLink
Log in

Adjuvante medikamentöse Therapie des malignen Melanoms

Adjuvant medical treatment of malignant melanoma

  • Leitthema
  • Published:
Der Onkologe Aims and scope

Zusammenfassung

Zahlreiche adjuvante Therapien des malignen Melanoms sind in den vergangenen Jahrzehnten erprobt worden. In prospektiv randomisierten Studien wies die systemische adjuvante Chemotherapie übereinstimmend im Gegensatz zu ersten Untersuchungen mit historischen Kontrollkollektiven keinen Vorteil für die Behandelten im Vergleich zu Unbehandelten auf. Auch unspezifische adjuvante Immuntherapien führten zu keinen signifikanten Vorteilen. IFN-α ist die erste und bisher einzige Substanz, die in der adjuvanten Therapie des malignen Melanoms zu signifikanten Vorteilen für die Behandelten führte. Die optimale Dosis und Dauer der Therapie muss jedoch noch ermittelt werden.

Abstract

Numerous adjuvant therapies for malignant melanoma have been evaluated in recent years. However, despite initial encouraging results, in many prospective randomized clinical studies, adjuvant chemotherapy did not lead to any benefit. Similarly, unspecific immunotherapy did not lead to any benefit for treated patients as compared to untreated controls. IFN-α is the first and so far only drug with significant benefit for melanoma patients in the adjuvant setting. Further studies will reveal the optimal dose and length of therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Literatur

  1. Beiteke U, Ruppert P, Garbe C et al. (1993) Adjuvante Therapie des primären malignen Melanoms mit natürlichem humanem Interferon beta. Hautarzt 44:365–371

    CAS  PubMed  Google Scholar 

  2. Cameron DA, Cornbleet MC, MacKie RM, Hunter JA, Gore M, Hancock B, Smyth JF (2001) Adjuvant interferon alpha 2b in high risk melanoma—the Scottish study. Br J Cancer 84:1146–1149

    Article  CAS  PubMed  Google Scholar 

  3. Cascinelli N, Belli F, MacKie RM, Santinami M, Bufalino R, Morabito A (2001) Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial. Lancet 358:866–869

    Article  CAS  PubMed  Google Scholar 

  4. Creagan ET, Dalton RJ, Ahmann DL, Jung SH, Morton RF, Langdon RMJ, Kugler J, Rodrigue LJ (1995) Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 13:2776–2783

    CAS  PubMed  Google Scholar 

  5. Czarnetzki BM, Macher E, Suciu S, Thomas D, Steerenberg PA, Rumke P (1993) Long – term adjuvant immunotherapy in stage I high risk malignant melanoma, comparing two BCG preparations versus non – treatment in a randomized multicenter study (EORTC protocol 18781). Eur J Cancer 29A:1237–1242

    Article  CAS  PubMed  Google Scholar 

  6. Dummer R, Hauschild A, Henseler T, Burg G (1998) Combined interferon-alpha and interleukin-2 adjuvant treatment for melanoma. Lancet 352:908–909

    CAS  Google Scholar 

  7. Eggermont AMM, Kleeberg UR, Ruiter DJ et al. (2001) European Organization for Research and Treatment of Cancer melanoma Group Trial Experience with more than 2,000 Patients, Evaluating Adjuvant Treatment With Low or Intermediate Doses of Interferon Alpha-2b. American Society of Clinical Oncology, 37th Annual meeting, 2001 Educational Book, pp 88–93

  8. Garbe C, Kapp A, Hauschild A, Djawari D, Reinhold D, Linse R, Elsner P (2002) Adjuvant treatment of patients with cutaneous melanoma and completely resected metastasis with vindesine versus observation alone. Preliminary evaluation of a randomised multicenter DeCOG Trial. Melanoma Res 12:A12–A13

    Google Scholar 

  9. Garbe C, Hauschild A, Linse R et al. (2002) Adjuvant treatment of patients with cutaneous melanoma and regional node metastasis with low dose interferon- or interferon- plus DTIC versus observation alone. Preliminary evaluation of a randomised multicenter DeCOG trial. Melanoma Res 12:A13–A14

    Google Scholar 

  10. Grob JJ, Dreno B, de la Salmoniere P et al. (1998) Randomised trail of interferon alpha-2b as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. Lancet 351:1905–1910

    Article  CAS  PubMed  Google Scholar 

  11. Hancock BW, Wheatley K, Harris S, Ives N, Harrison G, Horsman JM, Middleton MR, Thatcher N, Lorigan PC, Marsden JR, Burrows L, Gore M (2004) Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma. J Clin Oncol 22:53–61

    Article  CAS  PubMed  Google Scholar 

  12. Hauschild A, Volkenandt M, Garbe C (2000) Adjuvante medikamentöse Therapie des malignen Melanoms. Aktueller Wissensstand und derzeitige Multicenterstudien in den deutschsprachigen Ländern. Dtsch Med Wochenschr 125:1272–1278

    Article  CAS  PubMed  Google Scholar 

  13. Hauschild A, Weichenthal M, Balda BR et al. (2003) Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinical detectable node metastasis. J Clin Oncol 21:2883–2888

    Article  PubMed  Google Scholar 

  14. Hill GJ, Moss SE, Golomb FM et al. (1981) DTIC and combination therapy for melanoma, III: DTIC Surgical Adjuvant Study COG protocol 7040. Cancer 47:2556–2562

    PubMed  Google Scholar 

  15. Karg C, Garbe C, Orfanos CE (1990) Chemotherapie des malignen Melanoms—aktueller Stand. Hautarzt 41:56–65

    CAS  PubMed  Google Scholar 

  16. Kirkwood JM, Strawderman MH, Ernstoff MS et al. (1996) Interferon alfa-2b adjuvant therapy of high risk resected cutaneous melanoma. The Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14:7–17

    CAS  PubMed  Google Scholar 

  17. Kirkwood J, Agarwala SS (1998) Adjuvant systemic therapy. In: Balch CM, Houghton AN, Sober AJ, Soong S (eds) Cutaneous melanoma. Quality Medical Publishing, St. Louis: 451–459

  18. Kirkwood JM, Ibrahim JG, Sondak VK et al. (2000) High- and low-dose interferon alfa-2b in high risk melanoma: first analysis of intergroup trial E 1690. J Clin Oncol 18:2444–2458

    CAS  PubMed  Google Scholar 

  19. Kirkwood JM, Ibrahim JG, Sosman JA et al. (2001) High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIb-III melanoma: results of intergroup trial E1694. J Clin Oncol 19:2370–2380

    CAS  PubMed  Google Scholar 

  20. Kleeberg UR, Suciu S, Brocker EB et al. (2004) Final results of the EORTC 18871/DKG 80–1 randomised phase III trial. RIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3mm) or regional lymph node metastasis. Eur J Cancer 40:390–402

    Article  CAS  PubMed  Google Scholar 

  21. Koops HS, Vaglini M, Suciu S et al. (1998) Prophylactic isolated limb perfusion for localized, high-risk limb melanoma: Results of a multicenter randomized phase III trial. J Clin Oncol 16:2906–2912

    CAS  PubMed  Google Scholar 

  22. Lens MB, Dawes M (2002) Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials. J Clin Oncol 20:1818–1825

    Article  CAS  PubMed  Google Scholar 

  23. Meyskens FL, Kopecky K, Samson M et al. (1990) Recombinant human interferon gamma: Adverse effects in high-risk stage I and II cutaenous malignant melanoma. J Natl. Cancer Inst 82:1071

    Google Scholar 

  24. Pehamberger H, Soyer HP, Steiner A et al. (1998) Adjuvant interferon-alpha2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group. J Clin Oncol 16:1425–1429

    CAS  PubMed  Google Scholar 

  25. Retsas S, Quigley M, Pectasides D et al. (1994) Clinical and histologic involvement of regional lymph nodes in malignant melanoma. Adjuvant vindesine improves survival. Cancer 73:2119–2130

    CAS  PubMed  Google Scholar 

  26. Spitler LE, Grossbard ML, Ernsthoff MS et al. (2000) Adjuvant therapy of stage III and IV malignant melanoma using granulocyte-macrophage colony stimulating factor. J Clin Oncol 18:1614–1621

    CAS  PubMed  Google Scholar 

  27. Veronesi U, Adamus J, Aubert C (1982) A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma. N Engl J Med 307:913–916

    CAS  PubMed  Google Scholar 

  28. Volkenandt M, Schmidt M, Konz B et al. (1999) Klinisch-epidemiologische Daten von Patienten mit malignen Melanomen aus dem Bereich des Tumorzentrums München von 1977–1997. Hautarzt 50:470–478

    CAS  PubMed  Google Scholar 

  29. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suici S (2003) Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials. Cancer Treat Rep 29:241–252

    Article  CAS  Google Scholar 

Download references

Interessenkonflikt:

Der korrespondierende Autor versichert, dass keine Verbindungen mit einer Firma, deren Produkt in dem Artikel genannt ist, oder einer Firma, die ein Konkurrenzprodukt vertreibt, bestehen.

Author information

Authors and Affiliations

  1. Klinik und Poliklinik für Dermatologie und Allergologie der LMU München

    M. Volkenandt

  2. Klinik für Dermatologie, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel

    A. Hauschild

  3. Klinik für Dermatologie, Universitätsklinikum Tübingen, Tübingen

    C. Garbe

  4. Klinik und Poliklinik für Dermatologie und Allergologie der LMU München, Frauenlobstraße 9–11, 80337, München

    M. Volkenandt

Authors
  1. M. Volkenandt
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. A. Hauschild
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C. Garbe
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to M. Volkenandt.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Volkenandt, M., Hauschild, A. & Garbe, C. Adjuvante medikamentöse Therapie des malignen Melanoms. Onkologe 10, 710–716 (2004). https://doi.org/10.1007/s00761-004-0721-4

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00761-004-0721-4

Schlüsselwöorter

Keywords

Search

Navigation